# Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

**Authors:** Elena López-Andrade, Francisco Javier Manzano-Moreno, Virginia Taboada, Cristina Vallecillo, Laura Jiménez-Andújar, Marta Vallecillo-Rivas

PMC · DOI: 10.1007/s00784-026-06832-9 · Clinical Oral Investigations · 2026-03-25

## TL;DR

A clinical trial found that applying simvastatin gel with a collagen sponge after tooth extraction helps preserve alveolar bone height, aiding future dental treatments.

## Contribution

Demonstrates that topical simvastatin gel significantly preserves vertical alveolar bone height post-extraction compared to placebo.

## Key findings

- Test group showed mean vertical bone preservation of -0.30 mm vs. 1.28 mm loss in control group (p = 0.006).
- No significant difference in bone width preservation between groups.
- Simvastatin gel had excellent safety with no increased postoperative pain or swelling.

## Abstract

Alveolar ridge atrophy is an inevitable consequence following tooth extraction, leading to substantial vertical and horizontal bone loss and frequently complicating subsequent prosthetic rehabilitation. Simvastatin (SIM), known for its osteoinductive and anti-inflammatory properties, has shown promise in promoting local bone regeneration. This study aimed to evaluate the efficacy of topical application of a novel 1.2% SIM gel in preserving alveolar ridge dimensions following the surgical extraction of mandibular third molars, compared with a placebo.

A randomized, triple-blind clinical trial (RCT) was conducted involving 40 patients (n = 20 per group) requiring mandibular third molar extraction. Patients were randomly assigned to receive either the active 1.2% SIM gel (test group) or a placebo gel (control group). In both groups, the assigned gel was delivered using a collagen sponge as a carrier scaffold placed directly into the extraction socket. Cone Beam Computed Tomography (CBCT) scans were obtained pre-extraction (T0) and 12 weeks postoperatively (T1). The primary outcome was the dimensional change in vertical alveolar bone height (ΔH). Secondary and exploratory outcomes included changes in bone width (ΔW), bone density (Mean Gray Value), postoperative pain, and swelling.

The primary outcome analysis included 38 sockets (n = 19 per group). The Test Group (SIM) showed significantly greater vertical bone preservation, with a mean change in height of − 0.30 ± 1.79 mm (indicating preservation/gain), compared to the Control Group’s mean loss of 1.28 ± 1.50 mm (p = 0.006). No statistically significant difference was observed in exploratory bone width preservation (p > 0.05). The SIM gel demonstrated an excellent safety profile, with no significant differences regarding postoperative pain or swelling compared to the placebo.

The topical application of 1.2% SIM gel significantly improved vertical alveolar bone height preservation at 12 weeks compared to the placebo. This primary finding confirms the clinical benefit of local simvastatin delivery in maintaining the vertical dimension required for successful prosthetic treatment, while exploratory densitometric data also suggested an improvement in coronal bone mineralization. This simple, low-cost pharmacological approach is highly effective in mitigating post-extraction vertical bone loss.

## Linked entities

- **Chemicals:** simvastatin (PubChem CID 54454)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, SIM2 (SIM bHLH transcription factor 2) [NCBI Gene 6493] {aka HMC13F06, HMC29C01, SIM, bHLHe15}
- **Diseases:** allergy (MESH:D004342), inflammatory (MESH:D007249), bony (MESH:D018213), Swelling (MESH:D004487), dehiscence (MESH:D013529), ASA (MESH:D056807), periodontal defects (MESH:D010518), gain (MESH:D015430), tooth luxation (MESH:D014084), Trismus (MESH:D014313), Postoperative pain (MESH:D010149), hypercholesterolemia (MESH:D006937), Pain (MESH:D010146), penicillin allergy (MESH:D008586), bone defects (MESH:D001847), resorption of alveolar bone (MESH:D001862), Alveolar ridge atrophy (MESH:D016301), postoperative infection (MESH:D013530)
- **Chemicals:** Simvastatin (MESH:D019821), polypropylene (MESH:D011126), methylcellulose (MESH:D008747), articaine (MESH:D002355), epinephrine (MESH:D004837), chlorhexidine (MESH:D002710), ibuprofen (MESH:D007052), amoxicillin (MESH:D000658), cholesterol (MESH:D002784), collagen sponge (-), clindamycin (MESH:D002981)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013139/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013139/full.md

---
Source: https://tomesphere.com/paper/PMC13013139